{
  "schemaVersion": "wpf-flagship-release-v1",
  "release": "wpf-flagship-weight-management",
  "version": "1.1.0",
  "releaseDate": "2026-11-12",
  "scope": "Five weight-management studies of semaglutide, tirzepatide and retatrutide already evaluated in the WPF Flagship set. Not a systematic or complete review of these agents.",
  "license": {
    "name": "Creative Commons Attribution 4.0 International",
    "identifier": "CC-BY-4.0",
    "url": "https://creativecommons.org/licenses/by/4.0/"
  },
  "licenseScope": {
    "covered": [
      "The stable result identifiers (resultId) and the WPF citation strings",
      "WPF's classification of each study's design (kind)",
      "WPF-written estimand summaries (estimand), the analysis-plan section pointers, and the study-specific limitations (limitations)",
      "The field corrections and their basis notes, and the release changelog",
      "The selection, arrangement and structure of the dataset, and its CSV, BibTeX and JSON renderings",
      "WPF's source-locator records: where each displayed number sits in its source, the verification status, the automated-check outcomes and the list of what is unverified (verification)",
      "The release metadata and checksum file"
    ],
    "excluded": [
      "The cited papers and their abstracts, figures and tables (publishers and authors)",
      "ClinicalTrials.gov records, posted results, protocols and statistical analysis plans (linked, not redistributed)",
      "Regulator documents and product labels",
      "Bibliographic identifiers and reported numerical facts as stated by their sources",
      "WPF branding, logos and names",
      "WPF films, transcripts and website copy",
      "WPF repository code"
    ],
    "unclearAndExcluded": [
      "Fields that closely restate source reports: population, comparator, endpoint, followUp, result, uncertainty, discontinuation, funder and trial names. Ownership of this wording is unresolved, so it is outside the licensed scope until the Owner decides otherwise."
    ]
  },
  "suggestedAttribution": "World Peptide Foundation, \"WPF Flagship Weight Management\", version 1.1.0 (2026-11-12), https://www.worldpeptidefoundation.org/releases/wpf-flagship-weight-management/1.1.0/release.json. Licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Please indicate whether you made changes.",
  "releaseUrl": "https://www.worldpeptidefoundation.org/releases/wpf-flagship-weight-management/1.1.0/release.json",
  "supersedes": "1.0.0",
  "archivedVersions": [
    "https://www.worldpeptidefoundation.org/releases/wpf-flagship-weight-management/1.0.0/release.json"
  ],
  "resultsSha256": "6e4e9e2bab0e0c941af144d8d8796d66faf1d48818b2925929c51e3ef5ee60ad",
  "changelog": [
    {
      "version": "1.1.0",
      "date": "2026-11-12",
      "changes": [
        "Added \"Verify this result\": per-result source locators, verification status, automated-check outcomes and an explicit list of what is unverified (verification), plus designExplanation and versionedRecordUrl.",
        "Citations now name the release version, the versioned record and the primary source.",
        "STEP 1 and SURMOUNT-1 estimands now checked against their public analysis plans (estimand, analysisPlan fields). The SURMOUNT-1 registry results were found to report a different estimand from the displayed values; this is disclosed.",
        "Retatrutide phase 2 uncertainty now carries the registry's week-48 differences from placebo.",
        "No result identifier, trial, PMID or DOI changed. Version 1.0.0 remains published unchanged at its own URL."
      ]
    },
    {
      "version": "1.0.0",
      "date": "2026-11-12",
      "changes": [
        "First pinned release: 5 results with stable ids, identifiers, registry checks, estimands verified against public analysis plans where available, and design-level limitations.",
        "Applied CC BY 4.0 (Owner-approved) to the WPF-owned dataset; scope listed in LICENSE-NOTICE.txt and release.json.",
        "Corrected retatrutide:2 population and comparator fields (automated source validation; no human adjudication recorded)."
      ]
    }
  ],
  "fieldCorrections": [
    {
      "candidateId": "retatrutide:2",
      "field": "population",
      "previous": "Its dose-response relationships with respect to side effects, safety, and efficacy for the treatment of obesity are not known.",
      "corrected": "338 adults with a BMI of 30 or higher, or 27 to under 30 plus at least one weight-related condition",
      "basis": "PubMed abstract (PMID 37366315) and ClinicalTrials.gov NCT04881760 enrollment (338 actual). The stored value was a background sentence, not a population.",
      "checkedOn": "2026-11-11",
      "validation": "automated_source_validation",
      "humanAdjudication": null
    },
    {
      "candidateId": "retatrutide:2",
      "field": "interventionComparator",
      "previous": "We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or who had a BMI of 27 to less than 30 plus at least one weight-related condition.",
      "corrected": "Once-weekly subcutaneous retatrutide (1, 4, 8 or 12 mg, with differing starting doses in some arms) vs placebo for 48 weeks",
      "basis": "PubMed abstract (PMID 37366315). The stored value was the trial-design sentence, which names no intervention or comparator doses.",
      "checkedOn": "2026-11-11",
      "validation": "automated_source_validation",
      "humanAdjudication": null
    }
  ],
  "labels": {
    "validation": "automated_source_validation",
    "humanAdjudication": "none recorded"
  },
  "results": [
    {
      "resultId": "surmount-5-weight-72w",
      "candidateId": "semaglutide:1",
      "kind": "direct_head_to_head",
      "trial": "SURMOUNT-5 (phase 3b, open-label)",
      "agents": "Tirzepatide vs semaglutide",
      "pmid": "40353578",
      "doi": "10.1056/NEJMoa2416394",
      "registryId": "NCT05822830",
      "population": "751 adults with obesity, without type 2 diabetes",
      "comparator": "Maximum tolerated dose: tirzepatide 10 or 15 mg vs semaglutide 1.7 or 2.4 mg, once weekly",
      "endpoint": "Percent change in weight from baseline to week 72",
      "followUp": "72 weeks",
      "result": "-20.2% with tirzepatide vs -13.7% with semaglutide (least-squares means; P<0.001)",
      "uncertainty": "95% CI -21.4 to -19.1 (tirzepatide); -14.9 to -12.6 (semaglutide)",
      "discontinuation": "Not stated in the abstract; see the full text.",
      "funder": "Eli Lilly",
      "registryResultsPosted": true,
      "registryMasking": "None (open-label)",
      "estimand": "Modified treatment-regimen estimand (the plan's primary): participants included regardless of treatment discontinuation or other anti-obesity medication, except switching to the other study drug. The displayed -20.2% and -13.7% match the registry's ANCOVA result over the full analysis set, which is the method the plan specifies for this estimand (§4.3.1); the publication abstract does not name the estimand, so this is verified by method, not by an explicit label.",
      "analysisPlan": {
        "title": "SURMOUNT-5 Statistical Analysis Plan v3 (approved 23 Oct 2024), ClinicalTrials.gov NCT05822830",
        "url": "https://cdn.clinicaltrials.gov/large-docs/30/NCT05822830/SAP_001.pdf",
        "sections": "§1.1 Primary estimand; §4.3.1 primary analysis; §4.3.2 efficacy-estimand analysis"
      },
      "limitations": [
        "Open-label: participants and investigators knew the assigned drug (registry masking: none).",
        "Compared maximum tolerated doses; the results apply to adults with obesity without type 2 diabetes.",
        "Funded by the manufacturer of tirzepatide."
      ],
      "citation": "SURMOUNT-5 (phase 3b, open-label). Tirzepatide vs semaglutide. Primary source: https://doi.org/10.1056/NEJMoa2416394 (PMID 40353578; NCT05822830). Cited from World Peptide Foundation, WPF Flagship Weight Management, version 1.1.0, result surmount-5-weight-72w. Versioned record: https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.1.0&resultId=surmount-5-weight-72w | Result link: https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#surmount-5-weight-72w",
      "releaseVersion": "1.1.0",
      "designLabel": "Direct head-to-head randomized trial",
      "designExplanation": "Participants in one trial were randomly assigned to tirzepatide or semaglutide, so the difference between the two arms is a direct randomized comparison.",
      "verification": {
        "verifiedOn": "2026-11-12",
        "locators": [
          {
            "claim": "-20.2% with tirzepatide and -13.7% with semaglutide at week 72",
            "source": "ClinicalTrials.gov results",
            "locator": "NCT05822830, Results, Primary Outcome Measure 1, \"Percent Change From Baseline in Body Weight\" (Baseline, Week 72): LS mean -20.2 (arm \"15 mg or MTD - Tirzepatide\") and -13.7 (arm \"2.4 mg or MTD - Semaglutide\")",
            "url": "https://clinicaltrials.gov/study/NCT05822830?tab=results#outcome-measures",
            "status": "matched",
            "note": "The registry posts standard errors, not the confidence intervals shown on this page.",
            "machineCheck": {
              "kind": "ctgov_outcome",
              "nct": "NCT05822830",
              "outcomeIndex": 0,
              "title": "Percent Change From Baseline in Body Weight",
              "timeFrame": "Baseline, Week 72",
              "values": [
                "-20.2",
                "-13.7"
              ]
            }
          },
          {
            "claim": "95% CIs -21.4 to -19.1 and -14.9 to -12.6; P<0.001",
            "source": "PubMed abstract",
            "locator": "Abstract, Results: \"least-squares mean percent change in weight at week 72 was -20.2% (95% CI, -21.4 to -19.1) with tirzepatide and -13.7% (95% CI, -14.9 to -12.6) with semaglutide (P<0.001)\"",
            "url": "https://pubmed.ncbi.nlm.nih.gov/40353578/#abstract",
            "status": "matched",
            "machineCheck": {
              "kind": "pubmed_abstract",
              "pmid": "40353578",
              "contains": [
                "-20.2%",
                "-21.4 to -19.1",
                "-13.7%",
                "-14.9 to -12.6",
                "751"
              ]
            }
          },
          {
            "claim": "Primary estimand and the method that produces the displayed values",
            "source": "Statistical analysis plan",
            "locator": "SAP v3 (23 Oct 2024): section 1.1 Primary estimand; section 4.3.1 primary analysis",
            "url": "https://cdn.clinicaltrials.gov/large-docs/30/NCT05822830/SAP_001.pdf",
            "status": "matched",
            "note": "The abstract does not name the estimand. The displayed values match the registry's ANCOVA over the full analysis set, which is the method the plan specifies for its primary (modified treatment-regimen) estimand."
          },
          {
            "claim": "Table or figure in the paper",
            "source": "Publisher full text",
            "locator": "NEJM, DOI 10.1056/NEJMoa2416394",
            "url": "https://doi.org/10.1056/NEJMoa2416394",
            "status": "not_accessible",
            "note": "Publisher full text is not open access and was not readable by WPF (HTTP 403), so table and figure numbers are not claimed."
          }
        ],
        "unverified": [
          "The table or figure in the published paper that shows these numbers: not located, because the full text was not accessible.",
          "Discontinuation rates for each arm: not stated in the abstract and not read from the full text.",
          "The authors' own limitations section: not reviewed."
        ],
        "automatedChecks": [
          {
            "check": "Displayed point estimates and confidence limits found in the PubMed abstract and (point estimates) in the registry's posted results",
            "outcome": "Passed on 2026-11-12"
          }
        ],
        "humanReview": "none recorded"
      },
      "versionedRecordUrl": "https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.1.0&resultId=surmount-5-weight-72w",
      "analysisPlanUrl": "https://cdn.clinicaltrials.gov/large-docs/30/NCT05822830/SAP_001.pdf",
      "analysisPlanSections": "§1.1 Primary estimand; §4.3.1 primary analysis; §4.3.2 efficacy-estimand analysis",
      "registryCheckedOn": "2026-11-11",
      "detailUrl": "https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#surmount-5-weight-72w"
    },
    {
      "resultId": "step-1-weight-68w",
      "candidateId": "semaglutide:4",
      "kind": "separate_placebo_controlled",
      "trial": "STEP 1 (double-blind)",
      "agents": "Semaglutide 2.4 mg vs placebo, plus lifestyle intervention",
      "pmid": "33567185",
      "doi": "10.1056/NEJMoa2032183",
      "registryId": "NCT03548935",
      "population": "1,961 adults with BMI 30 or more (27 or more with a weight-related condition), without diabetes",
      "comparator": "Placebo plus lifestyle intervention (2:1 randomization)",
      "endpoint": "Percent change in body weight and weight reduction of at least 5% (coprimary)",
      "followUp": "68 weeks",
      "result": "-14.9% with semaglutide vs -2.4% with placebo; estimated difference -12.4 percentage points",
      "uncertainty": "Difference 95% CI -13.4 to -11.5",
      "discontinuation": "Primary estimand assessed effects regardless of treatment discontinuation or rescue interventions.",
      "funder": "Novo Nordisk",
      "registryResultsPosted": true,
      "registryMasking": "Quadruple",
      "estimand": "Treatment-policy primary estimand: effects regardless of adherence and of other anti-obesity treatment or rescue (the publication abstract's wording is \"regardless of treatment discontinuation or rescue interventions\"). The displayed difference of -12.4 points (95% CI -13.4 to -11.5) matches the registry's ANCOVA treatment difference, the method the plan specifies for this estimand. The arm values -14.9% and -2.4% are verified in the abstract only; the registry posts different, observed means.",
      "analysisPlan": {
        "title": "STEP 1 Statistical Analysis Plan (redacted, document dated 3 Jul 2020), ClinicalTrials.gov NCT03548935",
        "url": "https://cdn.clinicaltrials.gov/large-docs/35/NCT03548935/SAP_003.pdf",
        "sections": "§1.1.4 Estimands (primary estimand); §2.3.1 primary endpoint analysis"
      },
      "limitations": [
        "Both arms also received a lifestyle intervention, so the effect is of semaglutide added to lifestyle support.",
        "Enrolled adults without diabetes; not evidence for people with type 2 diabetes.",
        "Funded by the manufacturer of semaglutide."
      ],
      "citation": "STEP 1 (double-blind). Semaglutide 2.4 mg vs placebo, plus lifestyle intervention. Primary source: https://doi.org/10.1056/NEJMoa2032183 (PMID 33567185; NCT03548935). Cited from World Peptide Foundation, WPF Flagship Weight Management, version 1.1.0, result step-1-weight-68w. Versioned record: https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.1.0&resultId=step-1-weight-68w | Result link: https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#step-1-weight-68w",
      "releaseVersion": "1.1.0",
      "designLabel": "Separate placebo-controlled trial (not a head-to-head)",
      "designExplanation": "This drug was compared with placebo in its own trial. Setting two trials side by side is an indirect comparison across different populations, durations and designs, so their percentages cannot be subtracted.",
      "verification": {
        "verifiedOn": "2026-11-12",
        "locators": [
          {
            "claim": "-14.9% with semaglutide vs -2.4% with placebo; difference -12.4 points (95% CI -13.4 to -11.5)",
            "source": "PubMed abstract",
            "locator": "Abstract, Results: \"-14.9% in the semaglutide group as compared with -2.4% with placebo, for an estimated treatment difference of -12.4 percentage points (95% CI, -13.4 to -11.5; P<0.001)\"",
            "url": "https://pubmed.ncbi.nlm.nih.gov/33567185/#abstract",
            "status": "matched",
            "machineCheck": {
              "kind": "pubmed_abstract",
              "pmid": "33567185",
              "contains": [
                "-14.9%",
                "-2.4%",
                "-12.4 percentage points",
                "-13.4 to -11.5",
                "1961"
              ]
            }
          },
          {
            "claim": "Treatment difference -12.4 (95% CI -13.4 to -11.5)",
            "source": "ClinicalTrials.gov results",
            "locator": "NCT03548935, Results, Primary Outcome Measure 1, \"Change in Body Weight (%)\" (Baseline to week 68): first analysis, ANCOVA treatment difference -12.44 (95% CI -13.37 to -11.51)",
            "url": "https://clinicaltrials.gov/study/NCT03548935?tab=results#outcome-measures",
            "status": "matched",
            "note": "The entry lists two analyses without naming their observation periods; the first is taken to be the in-trial analysis because it matches the publication.",
            "machineCheck": {
              "kind": "ctgov_outcome",
              "nct": "NCT03548935",
              "outcomeIndex": 0,
              "title": "Change in Body Weight (%)",
              "timeFrame": "Baseline (week 0) to week 68",
              "values": [
                "-15.6",
                "-2.8",
                "-16.9",
                "-3.1"
              ]
            }
          },
          {
            "claim": "-14.9% and -2.4% (the arm values)",
            "source": "ClinicalTrials.gov results",
            "locator": "Same outcome measure: arm values are -15.6 vs -2.8 (in-trial period) and -16.9 vs -3.1 (on-treatment period)",
            "url": "https://clinicaltrials.gov/study/NCT03548935?tab=results#outcome-measures",
            "status": "different_value",
            "note": "The registry posts observed means by observation period (with standard deviations). The -14.9% and -2.4% shown here are the publication's model estimates and are verified in the abstract only."
          },
          {
            "claim": "Primary estimand: effects regardless of treatment discontinuation or rescue interventions",
            "source": "Statistical analysis plan",
            "locator": "SAP (document dated 3 Jul 2020, redacted): section 1.1.4 Estimands, \"Primary estimand\" (\"treatment policy\": regardless of adherence and of initiation of other anti-obesity therapies); section 2.3.1 Primary endpoint, analyses addressing the primary estimand (ANCOVA, multiple imputation from retrieved participants)",
            "url": "https://cdn.clinicaltrials.gov/large-docs/35/NCT03548935/SAP_003.pdf",
            "status": "matched",
            "note": "Section numbering inside this redacted SAP is irregular (the estimand subsections are numbered 1.1.1.3 and 1.1.1.4 under 1.1.4)."
          },
          {
            "claim": "Table or figure in the paper",
            "source": "Publisher full text",
            "locator": "NEJM, DOI 10.1056/NEJMoa2032183",
            "url": "https://doi.org/10.1056/NEJMoa2032183",
            "status": "not_accessible",
            "note": "Publisher full text is not open access and was not readable by WPF (HTTP 403), so table and figure numbers are not claimed."
          }
        ],
        "unverified": [
          "The table or figure in the published paper that shows these numbers: not located, because the full text was not accessible.",
          "The authors' own limitations section: not reviewed.",
          "Which observation period (in-trial or on-treatment) each registry analysis belongs to: inferred from order, not labelled by the registry."
        ],
        "automatedChecks": [
          {
            "check": "Abstract values found; registry treatment difference and its confidence interval equal the displayed difference",
            "outcome": "Passed on 2026-11-12. The arm values -14.9% and -2.4% are not in the registry entry (see above)."
          }
        ],
        "humanReview": "none recorded"
      },
      "versionedRecordUrl": "https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.1.0&resultId=step-1-weight-68w",
      "analysisPlanUrl": "https://cdn.clinicaltrials.gov/large-docs/35/NCT03548935/SAP_003.pdf",
      "analysisPlanSections": "§1.1.4 Estimands (primary estimand); §2.3.1 primary endpoint analysis",
      "registryCheckedOn": "2026-11-11",
      "detailUrl": "https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#step-1-weight-68w"
    },
    {
      "resultId": "surmount-1-weight-72w",
      "candidateId": "tirzepatide:4",
      "kind": "separate_placebo_controlled",
      "trial": "SURMOUNT-1 (phase 3, double-blind)",
      "agents": "Tirzepatide 5, 10 or 15 mg vs placebo",
      "pmid": "35658024",
      "doi": "10.1056/NEJMoa2206038",
      "registryId": "NCT04184622",
      "population": "2,539 adults with BMI 30 or more, or 27 or more with a weight-related complication, excluding diabetes",
      "comparator": "Placebo (1:1:1:1 randomization), including a 20-week dose-escalation period",
      "endpoint": "Percent change in weight and weight reduction of 5% or more (coprimary)",
      "followUp": "72 weeks",
      "result": "-15.0%, -19.5% and -20.9% with 5, 10 and 15 mg vs -3.1% with placebo",
      "uncertainty": "95% CI -15.9 to -14.2, -20.4 to -18.5, -21.8 to -19.9; placebo -4.3 to -1.9",
      "discontinuation": "Treatment-regimen estimand assessed effects regardless of treatment discontinuation, intention-to-treat population.",
      "funder": "Eli Lilly",
      "registryResultsPosted": true,
      "registryMasking": "Double",
      "estimand": "The abstract states a treatment-regimen estimand (regardless of treatment discontinuation, intention-to-treat). The analysis plan calls the matching estimand \"hybrid\" (regardless of adherence; ANCOVA with multiple imputation, §6.13.1.2). The registry's posted results (-16.0%, -21.4%, -22.5% vs -2.4%) are a different, efficacy-style analysis that excludes data after drug was stopped, so they do not check the displayed values. The plan also says publications would follow the efficacy estimand, which differs from the abstract; this is reported, not resolved.",
      "analysisPlan": {
        "title": "SURMOUNT-1 Statistical Analysis Plan version 2 (28 Sep 2021), ClinicalTrials.gov NCT04184622",
        "url": "https://cdn.clinicaltrials.gov/large-docs/22/NCT04184622/SAP_001.pdf",
        "sections": "§6.2 General Considerations (estimands); §6.13 Efficacy Analyses; §6.13.1.1 efficacy estimand; §6.13.1.2 hybrid estimand"
      },
      "limitations": [
        "Enrolled adults without diabetes; not evidence for people with type 2 diabetes.",
        "The 72-week period included a 20-week dose escalation, so full-dose exposure was shorter than 72 weeks.",
        "Funded by the manufacturer of tirzepatide."
      ],
      "citation": "SURMOUNT-1 (phase 3, double-blind). Tirzepatide 5, 10 or 15 mg vs placebo. Primary source: https://doi.org/10.1056/NEJMoa2206038 (PMID 35658024; NCT04184622). Cited from World Peptide Foundation, WPF Flagship Weight Management, version 1.1.0, result surmount-1-weight-72w. Versioned record: https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.1.0&resultId=surmount-1-weight-72w | Result link: https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#surmount-1-weight-72w",
      "releaseVersion": "1.1.0",
      "designLabel": "Separate placebo-controlled trial (not a head-to-head)",
      "designExplanation": "This drug was compared with placebo in its own trial. Setting two trials side by side is an indirect comparison across different populations, durations and designs, so their percentages cannot be subtracted.",
      "verification": {
        "verifiedOn": "2026-11-12",
        "locators": [
          {
            "claim": "-15.0%, -19.5%, -20.9% (5, 10, 15 mg) vs -3.1% placebo, with confidence intervals",
            "source": "PubMed abstract",
            "locator": "Abstract, Results: \"-15.0% (95% CI, -15.9 to -14.2) with 5-mg ... -19.5% (95% CI, -20.4 to -18.5) with 10-mg ... -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo\"; Methods names the treatment-regimen estimand",
            "url": "https://pubmed.ncbi.nlm.nih.gov/35658024/#abstract",
            "status": "matched",
            "machineCheck": {
              "kind": "pubmed_abstract",
              "pmid": "35658024",
              "contains": [
                "-15.0%",
                "-15.9 to -14.2",
                "-19.5%",
                "-20.4 to -18.5",
                "-20.9%",
                "-21.8 to -19.9",
                "-3.1%",
                "-4.3 to -1.9",
                "treatment-regimen estimand",
                "2539"
              ]
            }
          },
          {
            "claim": "The registry's posted primary result",
            "source": "ClinicalTrials.gov results",
            "locator": "NCT04184622, Results, Primary Outcome Measure 1, \"Percent Change From Baseline in Body Weight (Primary Treatment Period)\" (Baseline, Week 72): -16.0 (5 mg), -21.4 (10 mg), -22.5 (15 mg) vs -2.4 (placebo)",
            "url": "https://clinicaltrials.gov/study/NCT04184622?tab=results#outcome-measures",
            "status": "different_value",
            "note": "These are not the displayed values. The registry analysis (mixed model) excludes data after study drug was stopped, which is the plan's efficacy-style analysis. The displayed values come from the publication's treatment-regimen analysis. Do not use this registry entry to check the displayed numbers.",
            "machineCheck": {
              "kind": "ctgov_outcome",
              "nct": "NCT04184622",
              "outcomeIndex": 0,
              "title": "Percent Change From Baseline in Body Weight (Primary Treatment Period)",
              "timeFrame": "Baseline, Week 72",
              "values": [
                "-16.0",
                "-21.4",
                "-22.5",
                "-2.4"
              ]
            }
          },
          {
            "claim": "Which estimand each set of numbers belongs to",
            "source": "Statistical analysis plan",
            "locator": "SAP version 2 (28 Sep 2021): section 6.2 General Considerations (two estimands, \"efficacy\" and \"hybrid\"); section 6.13 Efficacy Analyses (opening paragraph); section 6.13.1.1 efficacy estimand (MMRM, efficacy analysis set); section 6.13.1.2 hybrid estimand (ANCOVA with multiple imputation, full analysis set, regardless of adherence)",
            "url": "https://cdn.clinicaltrials.gov/large-docs/22/NCT04184622/SAP_001.pdf",
            "status": "matched",
            "note": "The abstract's \"treatment-regimen estimand ... regardless of treatment discontinuation\" corresponds in content to the plan's \"hybrid\" estimand; the plan does not use the label \"treatment-regimen\". The plan also says publications would be guided by the efficacy estimand, yet the abstract headlines the treatment-regimen values. This mismatch is reported, not resolved."
          },
          {
            "claim": "Table or figure in the paper",
            "source": "Publisher full text",
            "locator": "NEJM, DOI 10.1056/NEJMoa2206038",
            "url": "https://doi.org/10.1056/NEJMoa2206038",
            "status": "not_accessible",
            "note": "Publisher full text is not open access and was not readable by WPF (HTTP 403), so table and figure numbers are not claimed."
          }
        ],
        "unverified": [
          "The table or figure in the published paper that shows these numbers: not located, because the full text was not accessible.",
          "Whether the publication's body reports the efficacy-estimand values alongside the displayed ones: not checked, because the full text was not accessible.",
          "Why the plan's statement about publications differs from the abstract's headline estimand: unresolved.",
          "The authors' own limitations section: not reviewed."
        ],
        "automatedChecks": [
          {
            "check": "Displayed values and confidence limits found in the PubMed abstract; registry values compared and found to differ",
            "outcome": "Abstract: passed. Registry: differs by design (see above), 2026-11-12"
          }
        ],
        "humanReview": "none recorded"
      },
      "versionedRecordUrl": "https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.1.0&resultId=surmount-1-weight-72w",
      "analysisPlanUrl": "https://cdn.clinicaltrials.gov/large-docs/22/NCT04184622/SAP_001.pdf",
      "analysisPlanSections": "§6.2 General Considerations (estimands); §6.13 Efficacy Analyses; §6.13.1.1 efficacy estimand; §6.13.1.2 hybrid estimand",
      "registryCheckedOn": "2026-11-11",
      "detailUrl": "https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#surmount-1-weight-72w"
    },
    {
      "resultId": "retatrutide-phase2-weight-48w",
      "candidateId": "retatrutide:2",
      "kind": "separate_placebo_controlled",
      "trial": "Retatrutide phase 2 (double-blind)",
      "agents": "Retatrutide 1, 4, 8 or 12 mg vs placebo",
      "pmid": "37366315",
      "doi": "10.1056/NEJMoa2301972",
      "registryId": "NCT04881760",
      "population": "338 adults with BMI 30 or more, or 27 to under 30 plus at least one weight-related condition",
      "comparator": "Placebo (multiple dose arms, 2:1:1:1:1:2:2 randomization)",
      "endpoint": "Primary: percent change in body weight at 24 weeks. Secondary: at 48 weeks",
      "followUp": "48 weeks (primary endpoint at 24 weeks)",
      "result": "At 48 weeks: -8.7% (1 mg), -17.1% (4 mg), -22.8% (8 mg), -24.2% (12 mg) vs -2.1% placebo",
      "uncertainty": "Not reported in the abstract. ClinicalTrials.gov posts differences from placebo at week 48 (95% CI): 1 mg -6.57 (-8.94 to -4.20); 12 mg -22.11 (-24.92 to -19.31). The 4 mg and 8 mg groups are posted separately by starting dose.",
      "discontinuation": "Not stated in the abstract; see the full text.",
      "funder": "Eli Lilly",
      "registryResultsPosted": true,
      "registryMasking": "Double",
      "estimand": "Efficacy estimand: the plan's primary estimand, also applied to the 48-week secondary endpoint. Permanent discontinuation of study drug is handled by a hypothetical strategy, asking what the effect would be had participants adhered to treatment. The registry's 24- and 48-week results use a mixed-effects model that excludes data after discontinuation, consistent with this; the displayed 48-week values match the registry's secondary measure.",
      "analysisPlan": {
        "title": "Retatrutide phase 2 Statistical Analysis Plan V4.0 (approved 15 Dec 2022), ClinicalTrials.gov NCT04881760",
        "url": "https://cdn.clinicaltrials.gov/large-docs/60/NCT04881760/SAP_001.pdf",
        "sections": "§1.1 Primary estimand and estimands for secondary objectives; §4.3.2 main analytical approach"
      },
      "limitations": [
        "Phase 2 dose-finding trial of 338 adults split across seven arms, so each arm is small.",
        "The primary endpoint was at 24 weeks; the 48-week results are secondary.",
        "Funded by the manufacturer of retatrutide. A phase 3 outcome is not represented here."
      ],
      "citation": "Retatrutide phase 2 (double-blind). Retatrutide 1, 4, 8 or 12 mg vs placebo. Primary source: https://doi.org/10.1056/NEJMoa2301972 (PMID 37366315; NCT04881760). Cited from World Peptide Foundation, WPF Flagship Weight Management, version 1.1.0, result retatrutide-phase2-weight-48w. Versioned record: https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.1.0&resultId=retatrutide-phase2-weight-48w | Result link: https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#retatrutide-phase2-weight-48w",
      "releaseVersion": "1.1.0",
      "designLabel": "Separate placebo-controlled trial (not a head-to-head)",
      "designExplanation": "This drug was compared with placebo in its own trial. Setting two trials side by side is an indirect comparison across different populations, durations and designs, so their percentages cannot be subtracted.",
      "verification": {
        "verifiedOn": "2026-11-12",
        "locators": [
          {
            "claim": "48-week LS mean change: -8.7% (1 mg), -17.1% (4 mg), -22.8% (8 mg), -24.2% (12 mg) vs -2.1% placebo",
            "source": "PubMed abstract",
            "locator": "Abstract, Results: \"At 48 weeks, the least-squares mean percentage change ... was -8.7% in the 1-mg group, -17.1% in the combined 4-mg group, -22.8% in the combined 8-mg group, and -24.2% in the 12-mg group, as compared with -2.1% in the placebo group\"",
            "url": "https://pubmed.ncbi.nlm.nih.gov/37366315/#abstract",
            "status": "matched",
            "machineCheck": {
              "kind": "pubmed_abstract",
              "pmid": "37366315",
              "contains": [
                "-8.7%",
                "-17.1%",
                "-22.8%",
                "-24.2%",
                "-2.1%",
                "338"
              ]
            }
          },
          {
            "claim": "The same 48-week values in the registry",
            "source": "ClinicalTrials.gov results",
            "locator": "NCT04881760, Results, Secondary Outcome Measure 1 (\"Mean Percent Change From Baseline in Body Weight\", Baseline, Week 48): placebo -2.11, 1 mg -8.67, 12 mg -24.22; the 4 mg and 8 mg groups are posted as separate starting-dose arms (-16.32 and -17.83; -21.72 and -23.88)",
            "url": "https://clinicaltrials.gov/study/NCT04881760?tab=results#outcome-measures",
            "status": "matched",
            "note": "Primary outcome (week 24) is Outcome Measure 1 in the registry; the 48-week measure is the first secondary.",
            "machineCheck": {
              "kind": "ctgov_outcome",
              "nct": "NCT04881760",
              "outcomeIndex": 1,
              "title": "Mean Percent Change From Baseline in Body Weight",
              "timeFrame": "Baseline, Week 48",
              "values": [
                "-2.11",
                "-8.67",
                "-24.22",
                "-16.32",
                "-17.83",
                "-21.72",
                "-23.88"
              ]
            }
          },
          {
            "claim": "Uncertainty shown on this page (differences vs placebo with 95% CI)",
            "source": "ClinicalTrials.gov results",
            "locator": "Same outcome measure, statistical analyses: LS mean difference vs placebo, 1 mg -6.57 (95% CI -8.94 to -4.20); 12 mg -22.11 (-24.92 to -19.31)",
            "url": "https://clinicaltrials.gov/study/NCT04881760?tab=results#outcome-measures",
            "status": "matched",
            "note": "These are differences from placebo, not confidence intervals around each arm's own mean."
          },
          {
            "claim": "Primary estimand (efficacy; hypothetical strategy for permanent discontinuation) applies to the 48-week estimate",
            "source": "Statistical analysis plan",
            "locator": "SAP V4.0 (15 Dec 2022): section 1.1 Primary estimand and estimands for secondary objectives; section 4.3.2 main analytical approach",
            "url": "https://cdn.clinicaltrials.gov/large-docs/60/NCT04881760/SAP_001.pdf",
            "status": "matched",
            "note": "The registry population excludes data after discontinuation of study drug, consistent with the hypothetical strategy."
          },
          {
            "claim": "Table or figure in the paper",
            "source": "Publisher full text",
            "locator": "NEJM, DOI 10.1056/NEJMoa2301972",
            "url": "https://doi.org/10.1056/NEJMoa2301972",
            "status": "not_accessible",
            "note": "Publisher full text is not open access and was not readable by WPF (HTTP 403), so table and figure numbers are not claimed."
          }
        ],
        "unverified": [
          "The table or figure in the published paper that shows these numbers: not located, because the full text was not accessible.",
          "The 4 mg and 8 mg confidence intervals for the combined groups: the registry posts them by starting-dose arm, so no source value for the combined groups was read.",
          "Discontinuation rates: not stated in the abstract and not read from the full text.",
          "The authors' own limitations section: not reviewed."
        ],
        "automatedChecks": [
          {
            "check": "Participant-weighted mean of the two registry 4 mg arms (33 and 33 participants)",
            "outcome": "-17.07, consistent with the combined -17.1 (WPF computation; the source does not state this)"
          },
          {
            "check": "Participant-weighted mean of the two registry 8 mg arms (35 and 35 participants)",
            "outcome": "-22.80, consistent with the combined -22.8 (WPF computation; the source does not state this)"
          }
        ],
        "humanReview": "none recorded"
      },
      "versionedRecordUrl": "https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.1.0&resultId=retatrutide-phase2-weight-48w",
      "analysisPlanUrl": "https://cdn.clinicaltrials.gov/large-docs/60/NCT04881760/SAP_001.pdf",
      "analysisPlanSections": "§1.1 Primary estimand and estimands for secondary objectives; §4.3.2 main analytical approach",
      "registryCheckedOn": "2026-11-11",
      "detailUrl": "https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#retatrutide-phase2-weight-48w"
    },
    {
      "resultId": "jama-intern-med-2024-realworld",
      "candidateId": "tirzepatide:6",
      "kind": "observational_cohort",
      "trial": "Rodriguez and colleagues, JAMA Internal Medicine 2024: cohort study, not a randomized trial",
      "agents": "Tirzepatide vs semaglutide (formulations labeled for type 2 diabetes, on or off label)",
      "pmid": "38976257",
      "doi": "10.1001/jamainternmed.2024.2525",
      "registryId": null,
      "population": "41,222 US adults with overweight or obesity on semaglutide (32,029) or tirzepatide (9,193); 18,386 after propensity-score matching; 52.0% of the matched group had type 2 diabetes",
      "comparator": "Semaglutide vs tirzepatide, as prescribed",
      "endpoint": "On-treatment weight change at 3, 6 and 12 months",
      "followUp": "Up to 12 months, on-treatment",
      "result": "Tirzepatide users were more likely to reach 5%, 10% and 15% weight loss (hazard ratios 1.76, 2.54, 3.24)",
      "uncertainty": "Hazard-ratio 95% CIs 1.68-1.84, 2.37-2.73, 2.91-3.61. Weight differences favoring tirzepatide: -2.4% (95% CI -2.5 to -2.2) at 3 months, -4.3% (-4.7 to -4.0) at 6 months, -6.9% (-7.9 to -5.8) at 12 months",
      "discontinuation": "On-treatment analysis: follow-up ended at discontinuation for 55.9% (tirzepatide) and 52.5% (semaglutide), so results describe people while taking the drug and are not comparable to the intention-to-treat results above.",
      "funder": "See the source",
      "registryResultsPosted": null,
      "registryMasking": null,
      "estimand": "Not applicable: observational cohort with no randomized estimand. Follow-up ended at discontinuation for 55.9% of the tirzepatide and 52.5% of the semaglutide group.",
      "analysisPlan": null,
      "limitations": [
        "Observational and not randomized: matched groups can still differ in ways that were not measured.",
        "On-treatment analysis, so results describe people while they were taking the drug.",
        "Formulations labeled for type 2 diabetes were used on or off label, and 52.0% of the matched group had type 2 diabetes."
      ],
      "citation": "Rodriguez and colleagues, JAMA Internal Medicine 2024: cohort study, not a randomized trial. Tirzepatide vs semaglutide (formulations labeled for type 2 diabetes, on or off label). Primary source: https://doi.org/10.1001/jamainternmed.2024.2525 (PMID 38976257). Cited from World Peptide Foundation, WPF Flagship Weight Management, version 1.1.0, result jama-intern-med-2024-realworld. Versioned record: https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.1.0&resultId=jama-intern-med-2024-realworld | Result link: https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#jama-intern-med-2024-realworld",
      "releaseVersion": "1.1.0",
      "designLabel": "Observational cohort (not randomized)",
      "designExplanation": "Patients were not randomized. People who chose or were prescribed each drug were matched statistically, so differences can reflect factors that were not measured. Results describe time on treatment only.",
      "verification": {
        "verifiedOn": "2026-11-12",
        "locators": [
          {
            "claim": "Population: 41,222 adults (32,029 semaglutide; 9,193 tirzepatide); 18,386 after matching; 9,563 (52.0%) with type 2 diabetes",
            "source": "Open-access full text",
            "locator": "Results, \"Patient Characteristics\", first paragraph and Figure 1 (study flow diagram); the matched-cohort characteristics are in the Table",
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11231910/",
            "status": "matched",
            "machineCheck": {
              "kind": "pmc_text",
              "pmcid": "PMC11231910",
              "contains": [
                "41 222",
                "32 029",
                "9193",
                "18 386",
                "9563 (52.0%) had T2D"
              ]
            }
          },
          {
            "claim": "Hazard ratios 1.76, 2.54, 3.24 for 5%, 10%, 15% weight loss (with CIs)",
            "source": "Open-access full text",
            "locator": "Results, weight-loss thresholds paragraph and Abstract; Figure 2 shows the event probabilities",
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11231910/#ioi240039f2",
            "status": "matched",
            "note": "The hazard-ratio sentence cites Figure 3, whose legend is about mean percentage change, so which figure displays the hazard ratios is not settled here. The numbers themselves are in the text.",
            "machineCheck": {
              "kind": "pmc_text",
              "pmcid": "PMC11231910",
              "contains": [
                "1.76",
                "1.68",
                "1.84",
                "2.54",
                "2.37",
                "2.73",
                "3.24",
                "2.91",
                "3.61"
              ]
            }
          },
          {
            "claim": "Weight differences -2.4%, -4.3%, -6.9% at 3, 6, 12 months (with CIs)",
            "source": "Open-access full text",
            "locator": "Results, on-treatment weight change paragraph (cites Figure 3; Figure 4 is titled \"Treatment Effects Comparing Tirzepatide to Semaglutide\")",
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11231910/#ioi240039f4",
            "status": "matched",
            "note": "WPF read the text, not the figure images, so which figure displays these adjusted differences is unverified.",
            "machineCheck": {
              "kind": "pmc_text",
              "pmcid": "PMC11231910",
              "contains": [
                "−2.4%",
                "−4.3%",
                "−6.9%",
                "−7.9% to −5.8%"
              ]
            }
          },
          {
            "claim": "Follow-up ended by discontinuation for 55.9% (tirzepatide) and 52.5% (semaglutide)",
            "source": "Open-access full text",
            "locator": "Results, \"Patient Characteristics\" paragraph (5,140 and 4,823 patients)",
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11231910/",
            "status": "matched",
            "machineCheck": {
              "kind": "pmc_text",
              "pmcid": "PMC11231910",
              "contains": [
                "5140 patients (55.9%)",
                "4823 (52.5%)"
              ]
            }
          }
        ],
        "unverified": [
          "Which figure displays the hazard ratios and which displays the adjusted weight differences: WPF read the text, not the figure images.",
          "Funder: not read from the full text; see the source.",
          "The authors' limitations section: not reviewed."
        ],
        "automatedChecks": [
          {
            "check": "Displayed counts, percentages, hazard ratios and weight differences found in the open-access full text",
            "outcome": "Passed on 2026-11-12"
          }
        ],
        "humanReview": "none recorded"
      },
      "versionedRecordUrl": "https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.1.0&resultId=jama-intern-med-2024-realworld",
      "analysisPlanUrl": null,
      "analysisPlanSections": null,
      "registryCheckedOn": null,
      "detailUrl": "https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#jama-intern-med-2024-realworld"
    }
  ]
}
